United States Últimas notícias

Elon Musk's SpaceX is in talks with banks and investors to raise $40 billion to buy chips from Nvidia. Sarah Frier has more on "Bloomberg Open Interest."

Cosmos Health (NASDAQ:COSM) reported preliminary nine-month revenue of approximately $54.3 million for the period ended September 30, 2026.

Safe Pro Group (NASDAQ) expects third-quarter 2026 revenue to exceed $2.5 million, representing growth of more than 2,300% from $101,422 in the same quarter a year earlier.

Simon Leopold, Raymond James equity analyst, sees shares Nvidia rising to $515. The stock is trading near a record high with SpaceX reportedly in talks to raise $40 billion to buy Nvidia chips. Leopold is on "Bloomberg Surveillance."

Mark Cabana, co-head of global rates strategy at BofA Securities, says markets and economies around the world are starting to see the bite of higher rates and that the Federal Reserve needs to keep hikes on the table. He speaks on "Bloomberg Surveillance."

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) announced positive preclinical results for its Bisphosphocin compounds in animal models of urinary tract and pulmonary infections.

Eric Kutcher, McKinsey & Co. chair of North America, is very bullish on the US economy. He says there will be more jobs in 2035 then there are today. He says artificial intelligence is creating jobs and points out that software developers who help AI write code are in high demand. He appears on "Bloomberg Surveillance."

Lucas GC (NASDAQ:LGCL) reported its first-half financial results for the period ended June 30, 2026, generating total revenue of $35.74 million (RMB245.3 million).

Google (NASDAQ:GOOGL) and Unity (NYSE:U) announced a strategic partnership to combine artificial intelligence research with industry-leading engine technology for a new era of gaming.

AbbVie (NYSE:ABBV) received two FDA Breakthrough Therapy Designations for its investigational asset, telisotuzumab adizutecan (Temab-A).

TOYO (NASDAQ:TOYO) completed its Texas solar module capacity expansion to 2 GW, hosting a ribbon-cutting ceremony at its Humble facility.

BD (NYSE:BDX) announced nine-month AGILITY trial results showing its Revello Vascular Covered Stent met the primary endpoint with a 97.2% primary patency rate in iliac artery disease.